- Home
- DKI vs INTS Comparison
DKI vs INTS Comparison
Compare DKI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKI
- INTS
- Stock Information
- Founded
- DKI 2018
- INTS 2012
- Country
- DKI Hong Kong
- INTS United States
- Employees
- DKI N/A
- INTS N/A
- Industry
- DKI
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- DKI
- INTS Health Care
- Exchange
- DKI Nasdaq
- INTS Nasdaq
- Market Cap
- DKI 11.9M
- INTS 12.2M
- IPO Year
- DKI 2025
- INTS 2023
- Fundamental
- Price
- DKI $0.45
- INTS $0.41
- Analyst Decision
- DKI
- INTS Strong Buy
- Analyst Count
- DKI 0
- INTS 4
- Target Price
- DKI N/A
- INTS $4.50
- AVG Volume (30 Days)
- DKI 220.8K
- INTS 87.7M
- Earning Date
- DKI 11-28-2025
- INTS 11-06-2025
- Dividend Yield
- DKI N/A
- INTS N/A
- EPS Growth
- DKI N/A
- INTS N/A
- EPS
- DKI 26.19
- INTS N/A
- Revenue
- DKI $10,204,329.00
- INTS N/A
- Revenue This Year
- DKI N/A
- INTS N/A
- Revenue Next Year
- DKI N/A
- INTS N/A
- P/E Ratio
- DKI $0.02
- INTS N/A
- Revenue Growth
- DKI 100.46
- INTS N/A
- 52 Week Low
- DKI $0.43
- INTS $0.19
- 52 Week High
- DKI $15.00
- INTS $3.18
- Technical
- Relative Strength Index (RSI)
- DKI N/A
- INTS 49.37
- Support Level
- DKI N/A
- INTS $0.38
- Resistance Level
- DKI N/A
- INTS $0.57
- Average True Range (ATR)
- DKI 0.00
- INTS 0.18
- MACD
- DKI 0.00
- INTS -0.02
- Stochastic Oscillator
- DKI 0.00
- INTS 11.18
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.